US Stock MarketDetailed Quotes

SYRS Syros Pharmaceuticals

Watchlist

1.6600
+0.0400+2.47%

Close Aug 23 16:00 ET

1.6304
-0.0296-1.78%

Post 19:48 ET

44.50MMarket Cap-381P/E (TTM)

Syros Pharmaceuticals Stock Forum

Jaguar8

Yesterday 07:16

NEWS

$Syros Pharmaceuticals (SYRS.US)$
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemi...

NercZ24

Aug 13 08:52

$Syros Pharmaceuticals (SYRS.US)$ lettttss gooooo

108S

Aug 13 06:48

$Syros Pharmaceuticals (SYRS.US)$ buy or not

Trytosaveabit

Aug 13 05:00

Hehehe!

$Syros Pharmaceuticals (SYRS.US)$ Look atdat! Up about 40% since i said “ could be a buy opportunity “ Hehehe

Trytosaveabit

Aug 12 17:02

Allow me to share the paragraph that add to my statement of why this could be a buy opportunity! NFA just thinking outloud

$Syros Pharmaceuticals (SYRS.US)$ We are disappointed by this unexpected outcome, especially for people living with AML,” said David A. Roth, M.D., Chief Medical Officer of Syros. “In our prior Phase 2 clinical trial, the doublet combination of tamibarotene and azacitidine delivered a 61% CR/CRi rate in newly diagnosed AML patients with RARA overexpression. This supports our c...

Jaguar8 : Yes scaled in on this drop.

Report
Reply

Cancel Reply
Trytosaveabit OP Jaguar8 : Very nice! I to started scaling in! Hehehe Great minds right! Well your great mind and my mush Mellon! Hehehe

Report
Reply

Cancel Reply
Arrayfunction : Thank you for pointing this out! Great job at not falling into the trap of missing the forest for the trees!
If you don't mind me plagiarizing for the sake of other folks who stumble across this post here's my gist:
- Phase 3 trials are exponentially more important than Phase 2 when looking at a company's potential.
- The results of a Phase 3 trial will determine whether or not a company can expect to generate revenue within the next few years. They are the last stop on the train to the FDA approving a drug for sale.
- Positive Phase 2 trial results don't actually guarantee a positive Phase 3 result by any means. Even if they did, Phase 3 studies take years just to run. Once you add in the timelines for data analysis, reporting writing, IRB/advisory meetings, that Phase 2 drug candidate could be 5+ years away from actually making any money.
- In this case, people panic sold after the failure of a Phase 2 study. But as Trytosaveabit is reminding us, they still have a Phase 3 trial that is soon to wrap up. If those results are positive, the share value is going to rocket. A few minutes of critical thinking turns a 80% price drop into an 80% off sale!
But there still is no way to know for sure the phase 3 trial will be positive or if the company will actually reach the market. So always take risk into account!

Report
Reply

Cancel Reply
Trytosaveabit OP Arrayfunction : Very nicely said! And way better than I could have ever even come close to! So yup have at it! I welcome your input / addition to my clumsy explanation! Thank you!

Report
Reply

Cancel Reply
Arrayfunction Trytosaveabit OP : Don't sell yourself short just because I am 2m tall! (I like that pun because it's true ) You just keep things efficient! And do all the hard work while I am over here giving presentations in the remedial class

Report
Reply

Cancel Reply

View more comments...

Trytosaveabit

Aug 12 16:48

Hmm?

$Syros Pharmaceuticals (SYRS.US)$ Could be a opportunity here? Hehehe

Jaguar8

Aug 12 15:19

NEWS

$Syros Pharmaceuticals (SYRS.US)$
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of enrollment in its SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. The trial compared a triplet regimen (tamibarotene, venetoclax, and azacitidine) to a doublet regimen (venetoclax and azacitidine) in newly diagnosed, unfit AML patients with RARA gene overexpression.
The decision was based on a prespe...

Trytosaveabit

Aug 1 05:32

Make a note!

$Syros Pharmaceuticals (SYRS.US)$ The company is expected to release crucial data from the SELECT-MDS-1 Phase 3 trial for newly diagnosed high-risk MDS patients by the fourth quarter of 2024

Arrayfunction

Jul 31 06:45

$Syros Pharmaceuticals (SYRS.US)$
Might be seeing an NDA as soon as next year if things keep looking up from the phase 3 results!
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update :: Syros Pharmaceuticals, Inc. (SYRS)

Trytosaveabit

May 14 05:49

$Syros Pharmaceuticals (SYRS.US)$ Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.86) by 88.37 percent. This is a 88.24 percent increase over losses of $(0.85) per share from the same period last year.

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall